Richard D. Kolodner Elected to Institute of Medicine

University of California, San Diego School of Medicine researchers Joseph G. Gleeson, MD, Howard Hughes Medical Institute investigator and professor of neurosciences and pediatrics, and Richard D. Kolodner, PhD, professor of medicine and Ludwig Cancer Research scientist, have been named new members of the Institute of Medicine (IOM), considered among the highest honors in the fields of health and medicine. … Read the full story from the UC San Diego News Center


Dr. Richard KolodnerGeneticist and biochemist Richard D. Kolodner, PhD, is a distinguished professor in the departments of medicine (Division of Hematology-Oncology) and cellular and molecular medicine at UC San Diego.

Kolodner co-leads the Laboratory of Cancer Genetics in the San Diego branch of the Ludwig Institute for Cancer Research, which is located at UC San Diego.

At the UC San Diego Moores Cancer Center, he co-leads the Cancer Genomes and Networks research program with Trey Ideker, PhD, and is a member of the faculty of the Cancer Therapeutics Training (CT2) Program.

He is also a member of the Institute for Genomic Medicine and the Biomedical Sciences graduate program.

Kolodner was elected to the National Academy of Sciences in 2000 and the American Academy of Arts and Sciences in 2008. His election to the Institute of Medicine brings to 10 the number of Department of Medicine faculty members who are members of the institute.

See other UC San Diego news stories about Dr. Kolodner and his work.

New Understanding of ‘Copper Pump’ in Cells Could Prime Discovery of Anti-Cancer Drugs

A team of University of California, San Diego researchers has made new discoveries about a copper-transporting protein in the membranes of human cells that drug-discovery scientists can co-opt for the development of new anti-cancer drugs…. Read the full story from the UCSD Newsroom


Dr. Stephen Howell
Stephen B. Howell, MD, was on the research team, which was led by Igor Tsigelny of the Department of Neurosciences and the San Diego Supercomputer Center. Dr. Howell is professor of medicine in the Division of Hematology-Oncology and a translational researcher at the UC San Diego Moores Cancer Center, where he is associate director for clinical research.

He also directs the Cancer Therapeutics Training Program (CT2) and co-leads, with Dr. David Cheresh, the Tumor Growth, Invasion and Metastasis Program.Read the study report in Cell Biochemistry and Biophysics